ES2071681T3 - Compuestos macrociclicos. - Google Patents
Compuestos macrociclicos.Info
- Publication number
- ES2071681T3 ES2071681T3 ES89900628T ES89900628T ES2071681T3 ES 2071681 T3 ES2071681 T3 ES 2071681T3 ES 89900628 T ES89900628 T ES 89900628T ES 89900628 T ES89900628 T ES 89900628T ES 2071681 T3 ES2071681 T3 ES 2071681T3
- Authority
- ES
- Spain
- Prior art keywords
- represent
- alkyl
- compounds
- groups including
- carbon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/01—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
- Steroid Compounds (AREA)
Abstract
Un procedimiento para producir un compuesto de la fórmula I, **fórmula** en donde cada par vecino de sustituyentes [R1 y R2], [R3 y R4] y [R5 y R 6 ], independientemente: a) representan dos átomos de hidrógeno vecinos o b) forman un segundo enlace entre los átomos de carbono vecinos a los que están unidos; R7 representa H, OH u O - alquilo C1-6 o, junto con R1 , puede representar = O; R8 representa H u OH; R10 representa alquilo C1-6, alquilo C1-6 sustituido con uno o más grupos hidroxi, alquenilo C2-6, alquenilo C2-6 sustituido con uno o más grupos hidroxi, o alquilo C1-6 sustituido con = O; X representa O, (H,OH) ó - CH2O -; Y representa O, (H,OH), N - NR11 R12 ó N- OR13 ; R11 y R12 , independientemente, representan H, alquilo C1-6, fenilo o tosilo; R13 representa H o alquilo C1-6; R20 y R 21 representan, independientemente, O, o pueden representar, independientemente, (R20 a,H) y (R 21 a,H), respectivamente; R20 a y R21 a representan, independientemente, OH, O - alquilo C1-6 u OCH2OCH2CH2OCH3; además, R20 a y R 21 a pueden representar juntos un átomo de oxígeno en un anillo de epóxido; R23 representa H; n es1 ó 2; además de sus significados anteriores, Y, R10 y R23 , juntoconlosátomos de carbono a los que están unidos, pueden representar un anillo heterocíclico de 5 o 6 miembros con contenido de N, S u O, que puede estar saturado o insaturado y que puede estar sustituido con uno o más grupos seleccionados de alquilo C1-6, hidroxi, alquilo C1-6 sustituido con uno o más grupo hidroxi, O - alquilo C1-6, bencilo y - CH2Se(C6H5); con la condición de que: (a) cuando [R3 y R4] y [R5 y R6] representan en cada caso un enlace carbono - carbono; R7 representa Ho un grupo OH; R8 representa H; R10 representa metilo, etilo, propilo o alilo; R20 a representa OCH3; y R21 a representa OH; entonces X e Y no representan ambos O; y (b) cuando [R1 y R 2 ] representandos átomos de hidrógeno vecinos; [R3 y R4 ] y[R5 y R 6 ] representan en cada caso un enlace carbono - carbono; R7 representa un grupo OH; R8 representa H; R10 representa alilo; R21 a representa OH; X e Y representan en cada caso O; y n es 2; entonces R20 no representa O ó (OH,H); y sus sales farmacéuticamente aceptables, que comprende: (a) producir un compuesto de fórmula I, en que uno o más de [R1 y R 2], [R3 y R4] ó [R5 y R6] representan dos átomos de hidrógeno vecinos, por reducción selectiva de un correspondiente grupo [R1 y R2], [R3 y R4] ó [R5 y R6] cuando representa un segundo enlace entre dos átomos de carbono vecinos en un correspondiente compuesto, (b) producir un compuesto de fórmula I, que contiene uno o más grupos hidroxi, por reducción selectiva deuno o más grupos C=O en un correspondiente compuesto, (c) producir un compuesto de fórmula I, que contiene un grupo C=C - C=O I OH por oxidación selectiva de un grupo C -C-C=O I OH en un correspondiente compuesto, (d) producir un compuesto de fórmula I, que contiene uno o más grupos alcoxi, por alquilación de uno o más grupos hidroxi en un correspondientecompuesto por reacción con un agente alquilante adecuado, (e) producir un compuesto de fórmula I, que contiene uno o más grupos hidroxilo, por desprotección de uno o más grupos hidroxi protegidos en un correspondiente compuesto en que el grupo protector se puede separar preferiblemente por hidrogenolisis, (f) producir un compuesto de fórmula I, que contiene un doble enlace carbono - carbono, por eliminación de HL a partir de un correspondiente compuesto en que L es un grupo lábil, (g) producir un compuesto de fórmula I, en que Y, R10 y R23 , junto con los átomos de carbono a los que están unidos, forman un anillo de tetrahidrofurano sustituido con un grupo CH2Se(C6H5), haciendo reaccionar un haluro de fenilselenilo con un correspondiente compuesto en el que Y es O y R10 es alilo, (h) producir un compuesto de fórmula I, que contiene un alcohol alílico, por oxidación selectiva de un grupo alilo en un correspondiente compuesto, (i) producir un compuesto de fórmula I, que contiene un grupo cetona, por oxidación de un grupo hidroxi en un correspondiente compuesto, (j) producir un compuesto de fórmula I, que contiene un diol vecino, por oxidación de un doble enlace carbono - carbono en un correspondiente compuesto, (k) producir un compuesto de fórmula I, que contiene un grupo aldehído, por escisión oxidante de un diol vecino en un correspondiente compuesto, (l) producir un compuesto de fórmula I, en que Y, R10 y R23 , junto con los átomos de carbono a los que están unidos, forman un anillo de pirrol, haciendo reaccionar amoníaco o una amina con un correspondiente compuesto, en que Y es O y R10 es - CH2CHO, (m) producir un compuesto de fórmula I, que contiene un grupo epóxido, por ciclación de un grupo **fórmula** en un correspondiente compuesto, (n) producir un compuesto de fórmula I, en que Y representa un grupo oxima, por reacción de un correspondiente compuesto en que Y es O, con una amina oxígeno - sustituida, (o) producir un compuesto de fórmula I, que contiene un grupo COCH3, por oxidación de un grupo alqueno terminal en un correspondiente compuesto, (p) producir un compuesto de fórmula I, en que X representa-CH2O - , por reacción de un correspondiente compuesto en que X es O, con diazometano, (q) producir un compuesto de fórmula I, en que Y es una hidrazona o un derivado de hidrazona, haciendo reaccionar un correspondiente compuesto en que Y es O, con hidrazina o una hidrazina sustituida.
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB878728821A GB8728821D0 (en) | 1987-12-09 | 1987-12-09 | Compounds |
GB878728820A GB8728820D0 (en) | 1987-12-09 | 1987-12-09 | Compounds |
GB888803373A GB8803373D0 (en) | 1988-02-13 | 1988-02-13 | Compound |
GB888803377A GB8803377D0 (en) | 1988-02-13 | 1988-02-13 | Compound |
GB888803370A GB8803370D0 (en) | 1988-02-13 | 1988-02-13 | Compound |
GB888803375A GB8803375D0 (en) | 1988-02-13 | 1988-02-13 | Compound |
GB888803371A GB8803371D0 (en) | 1988-02-13 | 1988-02-13 | Compound |
GB888803374A GB8803374D0 (en) | 1988-02-13 | 1988-02-13 | Compound |
GB888803372A GB8803372D0 (en) | 1988-02-13 | 1988-02-13 | Compound |
GB888809174A GB8809174D0 (en) | 1988-04-19 | 1988-04-19 | Compounds |
GB888817624A GB8817624D0 (en) | 1988-07-23 | 1988-07-23 | Compounds |
GB888818426A GB8818426D0 (en) | 1988-08-03 | 1988-08-03 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2071681T3 true ES2071681T3 (es) | 1995-07-01 |
Family
ID=27583057
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES89900628T Expired - Lifetime ES2071681T3 (es) | 1987-12-09 | 1988-12-02 | Compuestos macrociclicos. |
Country Status (16)
Country | Link |
---|---|
EP (2) | EP0323042A1 (es) |
JP (1) | JP2799208B2 (es) |
KR (1) | KR900700494A (es) |
CN (1) | CN1033458A (es) |
AT (1) | ATE120466T1 (es) |
AU (1) | AU630866B2 (es) |
CA (1) | CA1339128C (es) |
DE (1) | DE3853477T2 (es) |
DK (1) | DK387889A (es) |
ES (1) | ES2071681T3 (es) |
FI (1) | FI90550C (es) |
IE (1) | IE66163B1 (es) |
IL (1) | IL88629A (es) |
NO (1) | NO893166D0 (es) |
NZ (1) | NZ227251A (es) |
WO (1) | WO1989005304A1 (es) |
Families Citing this family (130)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3275305D1 (en) * | 1981-05-19 | 1987-03-05 | Firmadoor Australia Pty Ltd | Operator for a door |
EP0349061B1 (en) * | 1988-06-29 | 1995-03-29 | Merck & Co. Inc. | Immunosuppressant agent |
US5290772A (en) * | 1988-06-29 | 1994-03-01 | Merck & Co., Inc. | Immunosuppressant agent |
ATE131536T1 (de) * | 1988-08-01 | 1995-12-15 | Fujisawa Pharmaceutical Co | Fr-901154- und fr-901155-derivate, verfahren zu ihrer herstellung |
EP0356399A3 (en) * | 1988-08-26 | 1991-03-20 | Sandoz Ag | Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them |
EP0358508A3 (en) * | 1988-09-08 | 1991-03-20 | Merck & Co. Inc. | Novel immunosuppressant compound |
GB2225576B (en) * | 1988-11-29 | 1992-07-01 | Sandoz Ltd | Substituted azatricyclo derivatives and metabolites,their preparation and pharmaceutical compositions containing them |
EP0378320A3 (en) * | 1989-01-13 | 1990-11-28 | Merck & Co. Inc. | Microbial transformation product |
EP0378317A3 (en) * | 1989-01-13 | 1990-11-28 | Merck & Co. Inc. | Microbial transformation product of l-679,934 |
US4975372A (en) * | 1989-01-13 | 1990-12-04 | Merck & Co., Inc. | Microbial transformation product of L-683,590 |
US5268370A (en) * | 1989-01-13 | 1993-12-07 | Merck & Co., Inc. | Microbial transformation product of L-679,934 |
EP0388153B1 (en) * | 1989-03-15 | 1994-12-28 | Merck & Co. Inc. | Immunosuppressant agent |
EP0399579A1 (en) * | 1989-04-21 | 1990-11-28 | Merck & Co. Inc. | Macrolides having immunosuppressive activity |
US5068323A (en) * | 1989-04-21 | 1991-11-26 | Merck & Co., Inc. | Thermally re-arranged FK-506 derivatives having immunosuppressant activity |
US5138052A (en) * | 1989-06-13 | 1992-08-11 | Merck & Co., Inc. | L-683,590 microbial transformation product |
CA2018710A1 (en) * | 1989-06-13 | 1990-12-13 | Shieh-Shung T. Chen | L-683,590 microbial transformation product |
WO1990015805A1 (en) * | 1989-06-14 | 1990-12-27 | Sandoz Ltd | Heteroatoms-containing tricyclic compounds |
US5200411A (en) * | 1989-06-14 | 1993-04-06 | Sandoz, Ltd. | Heteroatoms-containing tricyclic compounds |
WO1991002736A1 (en) * | 1989-08-18 | 1991-03-07 | Fisons Plc | Macrocyclic compounds |
EP0413532A3 (en) * | 1989-08-18 | 1991-05-15 | Fisons Plc | Macrocyclic compounds |
GR1001225B (el) * | 1989-09-14 | 1993-06-30 | Fisons Plc | Νέαι μακροκυκλικαί ενώσεις και νέα μέ?οδος χρήσεως τους. |
KR0159766B1 (ko) * | 1989-10-16 | 1998-12-01 | 후지사와 토모키치로 | 양모제 조성물 |
US5215995A (en) * | 1989-10-16 | 1993-06-01 | Fujisawa Pharmaceutical Co., Ltd. | Hair revitalizing agent |
NZ235991A (en) * | 1989-11-09 | 1993-05-26 | Sandoz Ltd | Macrolide compounds and pharmaceutical compositions thereof |
US5352671A (en) * | 1989-11-09 | 1994-10-04 | Sandoz Ltd. | Heteroatoms-containing tricyclic compounds |
US5208228A (en) * | 1989-11-13 | 1993-05-04 | Merck & Co., Inc. | Aminomacrolides and derivatives having immunosuppressive activity |
IE904050A1 (en) * | 1989-11-13 | 1991-05-22 | Merck & Co Inc | Aminomacrolides and derivatives having immunosuppressive¹activity |
GB8925797D0 (en) * | 1989-11-15 | 1990-01-04 | Fisons Plc | Compositions |
EP0444829A3 (en) * | 1990-02-27 | 1992-06-03 | Fisons Plc | Immunosuppressive compounds |
US5260301A (en) * | 1990-03-01 | 1993-11-09 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical solution containing FK-506 |
US5064835A (en) * | 1990-03-01 | 1991-11-12 | Merck & Co., Inc. | Hydroxymacrolide derivatives having immunosuppressive activity |
US5296489A (en) * | 1990-03-13 | 1994-03-22 | Fisons | Immunosuppressive macrocyclic compounds |
JPH05505798A (ja) * | 1990-03-13 | 1993-08-26 | フアイソンズ・ピーエルシー | 免疫抑制マクロ環状化合物 |
CA2040551A1 (en) * | 1990-04-30 | 1991-10-31 | Mark T. Goulet | Deoxymacrolide derivatives having immunosuppressive activity |
EP0533930A1 (en) * | 1990-06-11 | 1993-03-31 | Fujisawa Pharmaceutical Co., Ltd. | Use of a macrolide compound such as fk 506 for manufacturing a medicament for treating idiopathic thrombocytopenic purpura and basedow's disease |
US5643901A (en) * | 1990-06-11 | 1997-07-01 | Fujisawa Pharmaceutical Co., Ltd. | Medicament for treating idiopathic thrombocytopenic purpura |
GB9014136D0 (en) * | 1990-06-25 | 1990-08-15 | Fujisawa Pharmaceutical Co | Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same |
US5342935A (en) * | 1990-06-25 | 1994-08-30 | Merck & Co., Inc. | Antagonists of immunosuppressive macrolides |
US5210030A (en) * | 1990-06-25 | 1993-05-11 | Merck & Co., Inc. | Process for selectively acylating immunomycin |
US5190950A (en) * | 1990-06-25 | 1993-03-02 | Merck & Co., Inc. | Antagonists of immunosuppressive macrolides |
CA2044846A1 (en) * | 1990-06-25 | 1991-12-26 | Thomas R. Beattie | Antagonists of immunosuppressive macrolides |
GB9014681D0 (en) * | 1990-07-02 | 1990-08-22 | Fujisawa Pharmaceutical Co | Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same |
MY110418A (en) * | 1990-07-02 | 1998-05-30 | Novartis Ag | Heteroatoms-containing tricyclic compounds. |
EP0466365A3 (en) | 1990-07-03 | 1992-04-15 | Merck & Co. Inc. | Novel immunosuppressant fermentation products of a microorganism |
GB9014881D0 (en) * | 1990-07-05 | 1990-08-22 | Fujisawa Pharmaceutical Co | Tricyclo compounds,a process for their production and a pharmaceutical composition containing the same |
GB2245561A (en) * | 1990-07-05 | 1992-01-08 | Fujisawa Pharmaceutical Co | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
US5023263A (en) * | 1990-08-09 | 1991-06-11 | American Home Products Corporation | 42-oxorapamycin |
US5023262A (en) * | 1990-08-14 | 1991-06-11 | American Home Products Corporation | Hydrogenated rapamycin derivatives |
IE912886A1 (en) * | 1990-08-18 | 1992-02-26 | Fisons Plc | Macrocyclic Compounds |
GB2247620A (en) * | 1990-09-07 | 1992-03-11 | Fujisawa Pharmaceutical Co | The use of macrolide compounds for cytomegalovirus infection |
US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
EP0480623A1 (en) * | 1990-10-11 | 1992-04-15 | Merck & Co. Inc. | New halomacrolides and derivatives having immunosuppressive activity |
GB2249027A (en) * | 1990-10-23 | 1992-04-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds for hepatic failure |
US5348966A (en) * | 1990-10-24 | 1994-09-20 | Fujisawa Pharmaceutical Co., Ltd. | Method for treating pyoderma and Sezary's syndrome using FK 506 and related compounds |
CA2054128A1 (en) * | 1990-10-29 | 1992-04-30 | Kevin M. Byrne | Process for the production of analogues of immunomycin |
PH31204A (en) * | 1990-11-02 | 1998-05-05 | Fujisawa Pharmaceutical Co | Pharmaceutical composition. |
CA2054983A1 (en) * | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
GB2249787A (en) * | 1990-11-19 | 1992-05-20 | Fujisawa Pharmaceutical Co | Lactone compounds |
GB9027471D0 (en) * | 1990-12-19 | 1991-02-06 | Fujisawa Pharmaceutical Co | Novel compound |
GB2252041A (en) * | 1991-01-23 | 1992-07-29 | Fujisawa Pharmaceutical Co | Use of macrolide compounds in treatment of autoimmune myocarditis |
WO1992013862A1 (en) * | 1991-02-05 | 1992-08-20 | Fujisawa Pharmaceutical Co., Ltd. | Lactone compounds |
JPH06501026A (ja) * | 1991-04-11 | 1994-01-27 | ファイザー・インコーポレーテッド | ストレプトミセス・ブレジェンシス由来の新規の免疫抑制剤 |
KR100237715B1 (ko) * | 1991-04-26 | 2000-02-01 | 후지야마 아키라 | 안과질환에 대한 마크로라이드 화합물의 용도 |
US5565560A (en) * | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
US5162334A (en) * | 1991-05-13 | 1992-11-10 | Merck & Co., Inc. | Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity |
US5250678A (en) | 1991-05-13 | 1993-10-05 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
CA2071332A1 (en) * | 1991-06-25 | 1992-12-26 | Laszlo R. Treiber | C-21 hydroxylated fk-506 antagonist |
US5225403A (en) * | 1991-06-25 | 1993-07-06 | Merck & Co., Inc. | C-21 hydroxylated FK-506 antagonist |
US5149701A (en) * | 1991-08-01 | 1992-09-22 | Merck & Co., Inc. | C-31 methylated FR-900520 cyclic hemiketal immunosuppressant agents |
US5273979A (en) * | 1991-08-01 | 1993-12-28 | Merck & Co., Inc. | C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent |
US5198358A (en) * | 1991-08-28 | 1993-03-30 | Merck & Co., Inc. | Microorganism for producing C-31 desmethyl FR-900520 cyclic hemiketal immunosuppressant agent |
US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
KR100351222B1 (ko) * | 1991-09-05 | 2002-09-05 | 아보트 러보러터리즈 | 매크로사이클릭 면역 조절제 및 이의 제조방법 |
US5708002A (en) * | 1991-09-05 | 1998-01-13 | Abbott Laboratories | Macrocyclic immunomodulators |
ZA926812B (en) | 1991-09-09 | 1993-04-28 | Merck & Co Inc | O-heteroaryl,o-alkylheteroaryl,o-alkenylheteroaryl and o-alkynylheteroaryl macrolides having immunosupressive activity |
US5252732A (en) * | 1991-09-09 | 1993-10-12 | Merck & Co., Inc. | D-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity |
US5208241A (en) * | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
US5817333A (en) * | 1991-10-31 | 1998-10-06 | Fujisawa Pharmaceutical Co., Ltd. | Liposome preparation containing a tricyclic compound |
US5164399A (en) * | 1991-11-18 | 1992-11-17 | American Home Products Corporation | Rapamycin pyrazoles |
US5221625A (en) * | 1992-01-10 | 1993-06-22 | Merck & Co., Inc. | Cyclcic FR-900520 microbial biotransformation agent |
GB9203265D0 (en) * | 1992-02-15 | 1992-04-01 | Fisons Plc | Pharmaceutically active compound |
ATE153027T1 (de) * | 1992-03-02 | 1997-05-15 | Pfizer | Zuckerderivate von makroliden |
CA2091194A1 (en) * | 1992-04-08 | 1993-10-09 | Richard D. Connell | 2-oxo-ethyl derivatives as immunosuppressants |
US5284840A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkylidene macrolides having immunosuppressive activity |
US5284877A (en) * | 1992-06-12 | 1994-02-08 | Merck & Co., Inc. | Alkyl and alkenyl macrolides having immunosuppressive activity |
US5264355A (en) * | 1992-07-02 | 1993-11-23 | Merck & Co., Inc. | Methlating enzyme from streptomyces MA6858 |
GB9218597D0 (en) * | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
GB9218027D0 (en) * | 1992-08-25 | 1992-10-14 | Fisons Plc | Novel method of treatment |
GB9218797D0 (en) * | 1992-09-04 | 1992-10-21 | Fisons Plc | Pharmacologically active compounds |
CA2106034A1 (en) * | 1992-09-24 | 1994-03-25 | Ralph J. Russo | 21-norrapamycin |
US5268282A (en) * | 1992-09-28 | 1993-12-07 | Merck & Co., Inc. | Cyclic FR-900520 microbial biotransformation agent |
US5290689A (en) * | 1992-09-28 | 1994-03-01 | Merck & Co., Inc. | New cyclic FR-900520 microbial biotransformation agent |
US5283183A (en) * | 1992-09-28 | 1994-02-01 | Merck & Co., Inc. | Cyclic FR-900520 microbial biotransformation agent |
US5268281A (en) * | 1992-09-28 | 1993-12-07 | Merck & Co., Inc. | Cyclic FR-900520 microbial biotransformation agent |
US5258389A (en) * | 1992-11-09 | 1993-11-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives |
DK0669127T3 (da) * | 1992-11-18 | 1999-12-06 | Fujisawa Pharmaceutical Co | Farmaceutisk præparat med forlænget virkning |
GB9227055D0 (en) * | 1992-12-29 | 1993-02-24 | Fujisawa Pharmaceutical Co | New use |
US5310901A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynlheteroarylrapamycin derivatives |
US5310903A (en) * | 1993-03-05 | 1994-05-10 | Merck & Co., Inc. | Imidazolidyl rapamycin derivatives |
GB2279006A (en) * | 1993-06-03 | 1994-12-21 | Fujisawa Pharmaceutical Co | Treatment of amyotrophic lateral sclerosis |
US5359060A (en) * | 1993-07-06 | 1994-10-25 | Pfizer, Inc. | Phosponated derivatives of macrolides |
US5612350A (en) * | 1993-11-30 | 1997-03-18 | Abbott Laboratories | Macrocyclic immunomodulators with novel cyclohexyl ring replacements |
US5880280A (en) * | 1994-06-15 | 1999-03-09 | Merck & Co., Inc. | Aryl, alkyl, alkenyl and alkynylmacrolides having immunosuppressive activity |
US5693648A (en) * | 1994-09-30 | 1997-12-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity |
PL184750B1 (pl) | 1994-10-26 | 2002-12-31 | Novartis Ag | Kompozycja w postaci emulsji do stosowania miejscowego |
AR004480A1 (es) * | 1995-04-06 | 1998-12-16 | Amico Derin C D | Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen |
SI1064942T1 (en) | 1998-03-26 | 2004-12-31 | Fujisawa Pharmaceutical Co., Ltd. | Sustained release preparation of a macrolide |
IL142165A0 (en) | 1998-10-02 | 2002-03-10 | Kosan Biosciences Inc | Polyketide synthase enzymes and recombinant dna constructs therefor |
GB9826656D0 (en) | 1998-12-03 | 1999-01-27 | Novartis Ag | Organic compounds |
US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
US20070032853A1 (en) | 2002-03-27 | 2007-02-08 | Hossainy Syed F | 40-O-(2-hydroxy)ethyl-rapamycin coated stent |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US6790228B2 (en) | 1999-12-23 | 2004-09-14 | Advanced Cardiovascular Systems, Inc. | Coating for implantable devices and a method of forming the same |
US6569867B2 (en) | 1999-10-01 | 2003-05-27 | Kosan Biosciences, Inc. | Polyketide derivatives |
AR035411A1 (es) * | 2000-12-29 | 2004-05-26 | Fujisawa Pharmaceutical Co | Uso de un derivado de tacrolimus para fabricar un agente neurotrofico, composiciones y articulos de fabricacion o kits que lo comprenden, metodo para fabricar un agente que lo comprende y tejidos e injertos con una celula nerviosa tratada con este compuesto |
KR100512021B1 (ko) * | 2002-07-25 | 2005-09-02 | 신득용 | Fk506을 이용한 세포의 노화를 억제하는 방법 및 배양배지 |
AU2003901023A0 (en) * | 2003-03-04 | 2003-03-20 | Fujisawa Pharmaceutical Co., Ltd. | New use |
US20050118344A1 (en) | 2003-12-01 | 2005-06-02 | Pacetti Stephen D. | Temperature controlled crimping |
CA2554045A1 (en) * | 2004-01-20 | 2005-07-28 | Astellas Pharma Inc. | Method for treating erectile dysfunction |
WO2007020853A1 (ja) | 2005-08-12 | 2007-02-22 | Astellas Pharma Inc. | 薬剤の標的蛋白質を同定する方法及び標的蛋白質を用いた糖尿病治療薬のスクリーニング方法 |
JP2009203162A (ja) * | 2006-06-05 | 2009-09-10 | Astellas Pharma Inc | マクロライド化合物の新規製造法 |
EP2457589A1 (en) | 2006-08-31 | 2012-05-30 | Astellas Pharma Inc. | Reverse targeting lipid vesicle |
TW200932240A (en) | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
EP2658855A2 (en) | 2010-12-31 | 2013-11-06 | Acies Bio d.o.o. | Novel polyketide compounds and methods of making same |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP3977995A1 (en) | 2014-10-28 | 2022-04-06 | Koushi Yamaguchi | Tacrolimus for ameliorating pregnancy conditions |
CN106074367A (zh) * | 2016-07-20 | 2016-11-09 | 中山大学中山眼科中心 | 含fk506类化合物/fkbp蛋白二聚体的药物组合物及其制备方法 |
TW201821076A (zh) | 2016-11-10 | 2018-06-16 | 瑞士商諾華公司 | Bmp增強劑 |
EP3834826A4 (en) | 2018-08-10 | 2022-07-27 | Koushi Yamaguchi | THERAPEUTIC AGENT FOR HUMORAL IMMUNITY-RELATED DISEASES IN THE MATERNO-FETAL RELATIONSHIP |
US20220062245A1 (en) | 2018-12-18 | 2022-03-03 | Koushi Yamaguchi | Agent for improving infertility, recurrent miscarriage, and state of pregnancy |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
US4650803A (en) * | 1985-12-06 | 1987-03-17 | University Of Kansas | Prodrugs of rapamycin |
EP0349061B1 (en) * | 1988-06-29 | 1995-03-29 | Merck & Co. Inc. | Immunosuppressant agent |
ATE131536T1 (de) * | 1988-08-01 | 1995-12-15 | Fujisawa Pharmaceutical Co | Fr-901154- und fr-901155-derivate, verfahren zu ihrer herstellung |
EP0356399A3 (en) * | 1988-08-26 | 1991-03-20 | Sandoz Ag | Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them |
-
1988
- 1988-12-02 JP JP1500404A patent/JP2799208B2/ja not_active Expired - Lifetime
- 1988-12-02 EP EP88311422A patent/EP0323042A1/en active Pending
- 1988-12-02 ES ES89900628T patent/ES2071681T3/es not_active Expired - Lifetime
- 1988-12-02 AU AU28228/89A patent/AU630866B2/en not_active Ceased
- 1988-12-02 EP EP89900628A patent/EP0346427B1/en not_active Expired - Lifetime
- 1988-12-02 AT AT89900628T patent/ATE120466T1/de not_active IP Right Cessation
- 1988-12-02 DE DE3853477T patent/DE3853477T2/de not_active Expired - Lifetime
- 1988-12-02 WO PCT/GB1988/001093 patent/WO1989005304A1/en active IP Right Grant
- 1988-12-07 CA CA000585220A patent/CA1339128C/en not_active Expired - Fee Related
- 1988-12-08 IE IE366288A patent/IE66163B1/en not_active IP Right Cessation
- 1988-12-08 NZ NZ227251A patent/NZ227251A/xx unknown
- 1988-12-08 IL IL8862988A patent/IL88629A/en not_active IP Right Cessation
- 1988-12-09 CN CN88108277A patent/CN1033458A/zh active Pending
-
1989
- 1989-08-04 NO NO893166A patent/NO893166D0/no unknown
- 1989-08-08 DK DK387889A patent/DK387889A/da not_active Application Discontinuation
- 1989-08-09 FI FI893750A patent/FI90550C/fi not_active IP Right Cessation
- 1989-08-09 KR KR1019890701504A patent/KR900700494A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP0346427B1 (en) | 1995-03-29 |
JPH02502463A (ja) | 1990-08-09 |
WO1989005304A1 (en) | 1989-06-15 |
NZ227251A (en) | 1990-02-26 |
FI90550C (fi) | 1994-02-25 |
DK387889D0 (da) | 1989-08-08 |
EP0346427A1 (en) | 1989-12-20 |
AU2822889A (en) | 1989-07-05 |
EP0323042A1 (en) | 1989-07-05 |
FI893750A0 (fi) | 1989-08-09 |
ATE120466T1 (de) | 1995-04-15 |
IL88629A (en) | 1994-04-12 |
IE66163B1 (en) | 1995-12-13 |
CA1339128C (en) | 1997-07-29 |
KR900700494A (ko) | 1990-08-13 |
NO893166L (no) | 1989-08-04 |
FI90550B (fi) | 1993-11-15 |
JP2799208B2 (ja) | 1998-09-17 |
CN1033458A (zh) | 1989-06-21 |
IE883662L (en) | 1989-06-09 |
DE3853477T2 (de) | 1995-11-09 |
DK387889A (da) | 1989-08-08 |
NO893166D0 (no) | 1989-08-04 |
DE3853477D1 (de) | 1995-05-04 |
AU630866B2 (en) | 1992-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2071681T3 (es) | Compuestos macrociclicos. | |
EP0421634A3 (en) | Bis(3,4-dialkylbenzylidene) sorbitol acetals and compositions containing same | |
HUT67691A (en) | 7-(substituted)-8-(substituted)-9-[(substituted-glycyl)amido]6-demethyl-6-deoxytetracyclines, pharmaceutical compositions containing them and process to prepare them | |
IL114829A (en) | Biphenyl isoxazole sulfonamide derivatives and pharmaceutical compositions containing the same | |
GR3014931T3 (en) | Immunomodulatory azaspiranes. | |
ATE121939T1 (de) | Ascorbinsäure-tocopheryl-phosphatdiester zur hemmung der maillard-reaktion. | |
ATE107875T1 (de) | Wässrige polyurethan dispersionen. | |
HUT55032A (en) | Process for producing 19-norsteroids comprising carbon chain substituted in 11beta position by amide or carbamagte group, as well as pharmaceutical compositions comprising such compounds as active ingredient | |
ATE161717T1 (de) | Antivirale mittel | |
GR3007460T3 (es) | ||
ATE110721T1 (de) | 2-alkyl-3-benzoylbenzofurane und diese enthaltende pharmazeutische zusammensetzungen. | |
IL90724A0 (en) | Novel esters and pharmaceutical compositions containing same | |
MX170732B (es) | Composicion de derivados de succinimida y su uso | |
OA09349A (fr) | "Nouveaux dérivés du 3-aminochromane, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent". | |
ES2062406T3 (es) | Nuevos compuestos de morfolinol, su preparacion y uso. | |
TW273555B (es) | ||
EP0414391A3 (en) | Aminoketone derivatives and use thereof | |
ZA835390B (en) | 7-acylthio-15,16-methylene-3-oxo-17-pregna-1,4-diene 21,17-carbolactones,their preparation and use as medicinal agents | |
GR3017916T3 (en) | 3,4-Disubstituted phenyl-heterocycles and their use. | |
NZ228803A (en) | Sulphonanilides and anti-hypertensive compositions | |
ATE34176T1 (de) | 2'-chloropentostatin, eine diese verbindung enthaltende pharmazeutische zusammensetzung und ein mikroorganismus zur herstellung dieser verbindung. | |
ATE93524T1 (de) | Mitomycinanaloge, verfahren zu ihrer herstellung und pharmazeutische zubereitungen. | |
FI903511A0 (fi) | Pyrrolo (2,1-b) tiazolderivat. | |
MY102247A (en) | Phosphorylated acylglycosides, their preparation and use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 346427 Country of ref document: ES |